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ATTEMPTS to evaluate tetra-sodium2-methyl-i : 4-naphthohydroquinone dipho-
sphate (Compound I, Synkavit) as a radiosensitiser in the radiotherapy of malig-
nanttumourshave beeninprogress sinceNovember, 1946. Atfirstthe compound
was used alone and in conjunction with palliative X-ray therapy in some very
advanced cases. It soon became evident that in general the compound alone had
no therapeutic effect in malignant tumours. Then a general survey was under-
taken of the use oflarge doses of Compound I mainly in conjunction with radio-
therapy in patients with various types of advanced malignant tumours. At the
same time, all cases of inoperable carcinoma of the bronchus were treated, if
possible, by the combination ofX-ray therapy and Compound I; the results were
assessed mainly by survival times from the first X-ray treatment and the first
sympton and were compared with those which had been obtained previously
in the same department with X-ray therapy only, and which were very similar
to the depressing results obtained by most ofthe workers. Slowly the difficulties
of this type of clinical investigation were appreciated. Moreover in 1950 erratic
results were encountered both in the clinical trials and in animal experiments.
It seems likely that these findings were attributable to the thermal instability of
Compound I in aqueous solution in the absence of oxygen (Mitchell and Simon-
Reuss, 1952). Muchmoreconsistentresultshavebeenobtained sincetheampoules
have been stored in a refrigerator at about 30 C.
The evidence obtained by these preliminary studies was sufficiently suggestive
to justifyfurther work, but the methods used were clearlyinadequate. It became
essential to employ properly designed methods for the clinical evaluation ofradio-
sensitisers. The importance of these methods was emphasised at the time by
their use in clinical evaluation of chemotherapeutic agents in tuberculosis (Medi-
cal Research Council, 1948, 1950). Investigations of this type in the study of
radiosensitisers have been in progress since April 1951; as yet the only results
available are for the treatment ofinoperable carcinoma ofthe bronchus.
The results of the earlier studies have been reported by Mitchell (1948, 1949a,
1949b, 1950, 1951). This work has been criticised by Gellhorn and Gagliano
(1950). Otte (1949) reported briefly on the combination of X-ray therapy and
some synthetic vitamin K substitutes in the treatment of300 patients with advan-
ced malignant tumours and claimed improved palliation. Berkman (1951)
obtained results very similar to those of Mitchell by the combined use of X-ray
therapy and Synkavit.J. S. MITCHELL
Selection of types of malignant tumourfor investigation.
It is suggested that a practical minimum requirement for usefulness of a
radiosensitising chemical agent is that its employment in combination with radio-
therapy should produce a mean survival time after treatment double that after
radiotherapy only, for the type of malignant tumour treated. Hence taking
into account the frequency distribution of the survival times, it is likely to be
necessary to observe the cases treated by combined therapy for an interval of
at least 6 times the mean survival after radiotherapy only. To this time must
be added the time necessary to accumulate an adequate number of cases.
This approach is limited to the study of types of malignant tumour in which
the results of present methods of treatment are bad and in which the time of
survival is short.
Inoperable carcinoma of the bronchus is an obvious choice for investigation
It is the only common type ofmalignant disease with a very short natural history.
Despite advances, only a small proportion of all cases of carcinoma of the bron-
chus are curable by surgery. Untreated patients are often very miserable. The
results of treatment of inoperable cases by present methods, including radical
X-ray therapy, are poor. Nevertheless X-ray therapy in general has sufficient
palliative value apart from prolongation of life per se, to justify attempts to
improve this.
WithX-raytherapyonly,inoperablecarcinomaofthebronchusappearstohave a
a rather uniform naturalhistory. Theresultsofmanyworkershavebeenreviewed
in a number of papers (e.g., Bjork, 1947; Shorvon, 1947: Ariel et al., 1950).
In one of the earliest studies Schinz and Zuppinger (1937) reported that for 69
cases, the mean survival time after the beginning of X-ray treatment was 4-4
months; 16 cases (23 per cent) lived more than 6 months and 4 cases more than
1 year. Dobbie (1944) found that of 111 cases receiving palliative X-ray therapy,
26 per cent lived more than 6 months, and of 48 cases treated by radical X-ray
therapy, 54 per cent lived more than 6 months after treatment. Fulton (1949)
reported the following mean survival times from the onset of symptoms: for
915 untreated cases 7-6 months, for 199 cases receiving palliative X-ray therapy
9 0 months and for 190 cases treated by radical X-ray therapy, 14-7 months.
The largest published series oftreated cases appears to be that ofAriel et al (1950).
The duration oflifefrom the onset ofsymptoms of723 patients who received X-ray
therapy and for whom adequate data were available averaged 12-8 months. Of
816 patients receiving X-ray therapy, the average duration of life after the first
X-ray treatment was 4-2 months. Of these, histological evidence was obtained
in 245 patients andtheir average survival from the first symptom was 14-3 months
and from the beginning of X-ray treatment 4-5 months. From Fig. 7 of this
paper, it can be deduced that of 729 patients, only 45 survived 8 months, 20
survived 12 months, 8 survived 18 months and none survived 3 years following
X-ray therapy. In this series, the best survival rate-4-7 months-was in a
group of 80 patients who received a total dose as measured in air of 5000-6000 r;
higher and lower doses were associated with poorer results. The relation between
survival time and tumour dose (and histology), has often been discussed, e.g.,
by Tenzel (1941), Adelman (1952). There appears to be a slow increase in mean
survival time with increasing tumour dose except perhaps at the highest doses.
Nevertheless, there is great individual variation. The survival time tends to be
slightly greater in squamous carcinoma than in anaplastic carcinoma, but some
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cases of adenocarcinoma, especially in women, have rather longer survival. The
mostimportant factorin determining survivalisthe extent ofspread ofthe disease
when treated.
This evidence suggests that in representative series of cases of inoperable
carcinoma of the bronchus receiving X-ray therapy, the mean survival from the
beginning of treatment is about 4-5 months. Hence an investigation of a thera-
peutic radiosensitiser is likely to yield a definite result in this disease in the time
taken to collect at least 200 cases, say 3 years in a single department, plus six
times the mean survival time after radiotherapy only, which is about 21 years,
that is at least about 5 years in all.
For any other form ofmalignant tumour with a substantially longer survival,
direct studies of the mean survival times for radiotherapy with and without the
radiosensitiserarenotpracticable. Itwouldseemto beessentialtodevisemethods
of estimation of the results based on the mortality during the first few years.
(cf. Boag, 1948, 1949, 1950.)
PRELIMINARY GENERAL SURVEY
By way of approach to the problem, a general survey was undertaken of the
use of Compound I mainly in conjunction with radiotherapy in the treatment of
patients with various types of advanced malignant tumours except carcinoma of
the bronchus. Survival studies were not practicable at this stage. The criterion
of assessment of the possible value of the compound was the observation of an
unexpectedly good clinical response. It is appreciated that this criterion is to
some extent unsatisfactory, and not necessarily sufficiently objective. It has
been applied stringently. To try to minimise its shortcomings, all the cases to
which it is applied have been followed until death, or for at least 3-1 years and in
assessing the results the proportion of cases showing unexpectedly good response
has been compared in the case of patients treated by means ofradiotherapy com-
bined with intravenous compound with those treated by radiotherapy combined
with intramuscular compound. The results of various types of treatment of
patients with advanced malignant tumours classified as inoperable, Stages III
and IV, and recurrent of all types except carcinoma of the bronchus using Com-
pound I in treatments from November, 1946 to July, 1909 inclusive, and assessed
up to 31 December, 1952, are summarised in Table I for the cases verified histo-
logically. An essentialy similar table has been prepared showing the rather
poorer results for 56 cases not confirmed histologically, but with reasonably
certain diagnosis. The cases allocated to this preliminary survey were the great
majority of the patients with advanced malignant tumours in which it was con-
sidered that present methods of treatment were not likely to give satisfactorily
results. When the survey was started it was not realised that the use ofthe com-
pound by intravenous injection was likely to be more effective than its use by
intramuscular injection. The allocation of the patients to treatments involving
the two mnethods ofadministration ofthe compound were certainly not a.t random,
and the possibility of bias by the use of intramuscular injection in the more
seriouslyillpatients cannot be excluded. However, there is no reason to suppose
that such bias would influence the proportion of cases showing unexpectedly
good clinical response.
The results- of the preliminary general survey summarised in Table I suggests
that the proportion ofcases showing unexpectedly good clinical response is greater
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with radiotherapy combined with the compound administered by intravenous
injection than with radiotherapy combined with the compound administered by
intramuscular injection. It is emphasised that this conclusion must not be
regarded as more than suggestive.
Of the 131 cases verified histologically, 11 survived 4 years or more after
treatment. Of these, 5 cases showed an unexpectedly good response. Three
oftheseweretreatedbymeansofradicalX-ray therapy combinedwithintravenous
compound-one case ofadvanced carcinoma ofthe ovary and body ofuterus with
peritoneal metastases; one case of advanced reticulo-sarcoma of bones and one
TABLE I.-General Survey.
The results of treatment of patients with advanced malignant tumours-
classified as inoperable, Stages III and IV and recurrent-of all types
except carcinoma of the bronchus, treated with Compound I (Synkavit)
from November, 1946, to July, 1949, and assessed to December 31, 1952.
Cases verified histologically.
Number of cases showing unexpectedly good response.
Total number in group treated.
A
Oral
Method of S
treatment. only.
Site:
Mouth
Antrum and ethmoid -
Nasopharynx
Larynx extrinsic (with
1 case intrinsic)
Post-cricoid and oeso-
phagus
Stomach
Colon and caecum
Rectum
Cervix uteri . . 0/1
Body of uterus
Ovary
Breast
Skin and lip
Miscellaneous
Oral
S
pre-
I-VS vious
only. RT.
0/1
1 /1
1/1
0/4
0/2
1/1
1/1
0/1
0/2
I-MS
pre-
vious
RT.
1/3
I-VS
pre-
vious
RT.
3 /3
Radical Radical Total
X-ray X-ray Pal- Pal- number
or or liative liative of
I radium radium X-ray X-ray cases
therapy therapy therapytherapy at
+ + + + each
I-MS. I-VS. I-MS. I-VS. site.
2 /8 5/11 0/2 0/3
2/4
0,1 - -
- l0/ 2i4 1/2
- 1/2 1/2 0/2
11 0/2
- ()02
- 1/1 2/3 0/
0 /1
2/2 1/5
- 0/1 0/4
2/4 2/4 3/6
1/4 0/2 2/3 1/2
0/1
1/6
1 /1
0/3
0/1
1/1
0/2
0/1
0/2
1/2
. 0/1 2/11 2/3 1/3 8/15 7 /20 18/35 2 j20 4/23 131
131 cases verified histologically: of these, 11 survived 4 years or more after treatment.
56 very similar cases not confirmed histologically but with reasonably certain diagnosis; of
these, 2 survived more than 4 years after treatment.
187 cases in all, followed for 31 years or more.
Summary of results: Number of cases showing unexpectedly good
response out of total number treated.
All sites: Radiotherapy I-VS. 28/77 The difference between the two series
Radiotherapy + I-MS. 13/65 may be regarded as suggestive if
J applicable, XC2 = 3-83, P 005.
All sites excluding Radiotherapy +1-VS. 27/63 The difference between the two series
stomach and rec- amay be significant if applicable:
tum: Radotherapy + I-MS 3/63J Xc2 = 6-19, P = 0-013.
All sites
31
5
2
7
7
10
6
6
7
2
10
7
16
15
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case of advanced netiro-fibro-lipo-sarcoma of neck. One case of advanced car-
cinoma ofthe body ofthe uterus was treated by means ofpalliative X-ray therapy
combined with intravenous compound, and one case of carcinoma of the tongue
recurrent after previous X-ray therapy was treated successfully by radical X-ray
therapy combined with intramuscular compound.
Of the 56 cases not confirmed histologically three survived more than 4 years
after treatment. Two of these showed an unexpectedly good response; one was
a woman aged 46, who had a Stage IV carcinoma ofthe breast with supraclavicular
glands, and was treated by means ofradical X-ray therapy combined with intra-
muscular compound, and the other was a case of a mixed parotid tumour which
had failed to respond to further X-ray therapy, but appeared to be checked and
rendered quiescent by intravenous compound onlv. An unexpected finding as
shown in Table I for histologically positive cases is that 8 of 1.) cases recurrent
after radiotherapy showed an unespectedly good result when treated with intra-
venous compound only. This is the only group in which any substantial pro-
portion of cases appeared to improve with the use of the compound alone; this
finding requires confirmation. It is emphasised that in general the compound
alone has no therapeutic effect in malignant tumours.
Preliminary Clinical Trials in Inoperable Carcinoma of the Bronchus
The initial studies of the ancillary use of Compound I on the survival times
of inoperable cases of carcinoma of the bronchus treated by X-ray therapy (Mit-
chell, 1948, 1951) were probably essential as a preliminary step to the design of
a more satisfactory clinical trial. It is useful to summarise the end resuLlts of
these studies.
An attempt was made to study the influence of the ancillary use of the com-
pound on the results of X-ray therapy by measurement of the time of survival
both after the first symptom and after the first X-ray treatment and comparison
of the survival times in the control group of cases, which was treated by X-ray
therapy only and in the treated group which received X-ray therapy together
with the compound. Theresults are treated by statistical methods. Itis sugges-
ted that estimation of the survival times, especially that from the beginning of
X-ray therapy, is the most reliable criterion for objective assessment ofthe results
of treatment. Special attention has been paid to the influence of the extent of
the disease, age and sex, the histology, the minimum tumour dose and overall
time of the X-ray therapy and the details of administration of the compound.
The general principles involved in the consideration ofthese factors are essentially
the same in these preliminary studies as in the later clinical trials and except where
relevant, will be discussed in this connection. An attempt has been made to
compare the effects of the compound as a radio sensitiser when administered by
intramuscular and by intravenous injection.
Selection of cases.
The group defined as the treated group of cases of inoperable carcinoma of
the bronchus received X-ray therapy together with the compound which was
administered byintravenous and/or intramuscular injection, together with supple-
mentary oral administration in a few cases. In the cases recorded, the first
X-ray dose in the combined treatment was given in the interval from May 1, 1947
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to December 31, 1949 inclusive. The results of treatment were reviewed as from
December 31, 1952. This group of cases ofinoperable carcinoma ofthe bronchus
comprises all those cases referred in which the diagnosis is accepted as proven
according to the criteria given below, with the exclusion of patients not likely to
benefit by palliative X-ray therapy. No technically operable cases and no post-
operative cases are included.
The control group consists of those cases of inoperable carcinoma of the bron-
chus selected according to the same criteria, which were treated by X-ray therapy
only, using similar methods, in the same department between 1943 and May, 1947.
The difficulties of this method of providing a control group are recognised and
include the possibility of introduction of serious errors of sampling. The use
of alternate cases as controls was attempted but was abandoned as impractical.
However, it has been shown that the relevant properties ofthe control and treated
groups apartfromthelength ofsurvival aftertreatment aresubstantially the same.
It is found that the results of X-ray treatment in the present control group are
substantially identical with those obtained in two large published series. (Fulton
1949, Ariel et al., 1950).
Classification of Cases.
In both control and treated groups the most important cases are those com-
pletely " verified histologically " by the following methods:
(a) bronchial biopsy; this sub-group consists of 11 control cases and 26
treated cases.
(b) post-mortem examination; this sub-group consists of 6 control cases
and 2 treated cases.
(c) biopsy of a homolateral supra-clavicular node, in conjunction with
typical bronchoscopic appearances; in this sub-group there was one
control case and one treated case.
The histological examination of the bronchial biopsy specimens was
inconclusive.
(d) the finding of cells consistent with malignancy in the sputum, together
with typical bronchoscopic appearances; there was only one case,
a control, in this sub-group (Table II) and in this case there were terminal
metastases in the liver.
Thus of the cases described as " verified histologically," there are in all, 19
inthe controlgroup, which was treated by X-ray therapy only, and 29 in the treated
group which received X-ray therapy combined with administration of the
compound.
The larger proportion of cases verified histologically at post-mortem examina-
tion in the control group than in the treated group is associated with the shorter
survival time and the larger proportion of cases dying in hospital.
In addition to the " histologically verified " cases, there are groups of control
and treated cases in which the diagnosis is reasonably certain though less satis-
factorily established. These groups are selected as follows:
(a) cases not verified histologically but with typical bronchoscopic appear-
ances, together with clinical and/or radiological evidence of metastases
or infiltration at any stage; this sub-group consists of 7 control cases
and 9 treated cases;
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TABLE II.-Clinical Therapeutic Trial of a Radiosensitiser.
SUMMARY OF RESULTS.
Treatment of inoperable cases of carcinoma of the bronchus with randomised allocation to alter-
native treatments, X-ray therapy combined with intravenous Compound I (X + I-VS) and X-ray
therapy combined with intramuscular Compound I (X + I-MS), which is the control group.
Results assessed May 31, 1953. Cases No. 1-91 inclusive in which the first X-ray treatment was
given between April 1, 1951, and December 31, 1952.
Treatable less advanced male cases.
Selected from these cases are those with no evidence of extra-thoracic spread or metastases in
ribs at the first X-ray treatment and those in which the minimum tumour dose was not less than
1200 r. For the present purpose, cases treated surgically at any stage, and female patients are
excluded. Survival is estimated in months to the nearest month from the first X-ray treatment
and also from the first symptom.
Number of cases surviving 8 months or
Group. more from first X-ray treatment.
Total number of cases in each group.
X + I-VS. X + I-MS.
(a) Histology positive (one p.m. and sputum, others
bronchial biopsy) . . . . . 6/8 4/13
(b) Conclusive evidence ofmalignant cells in sputum
and /or bronchial aspirate . . . . 3/4* 0/3
(c) Reasonably certain diagnosis with typical bron-
choscopic and radiological appearances, and
clinical course . . . . . . 2/2 0/3
Pooled Groups (a), (b) and (c) . . . 11/14 4/19
* In this group is included one case surviving 4 months from the first X-ray
treatment and 10 months from the first symptom which was given intra-muscular
compound because of incorrect suspicion of cerebral metastases.
The difference between the proportion surviving 8 months or more from the first X-ray treatment
in the two series is statistically significant; for the pooled Groups (a), (b) and (c), x[1]2 = 10-76, so
that P = 0-001, and for the pooled Groups (a) and (b), x[1]2 = 6-891, so that P = 0-009.
Survival from the first symptom is a rather less sensitive and less objective test. In the pooled
Groups (a), (b) and (c), the proportions surviving 12 months or more from the first symptom in the
series X + I-VS and X + I-MS are respectively 11 /14 and 8/19; X[1]2 = 4-389, so that P = 0-037,
which may be regarded as significant.
Number of cases surviving 8 months or
Other ca8es. more from first X-ray treatment.
Total number of cases in each group.
X + I-VS. X + I-MS.
(d) Verified as in (a) and (b) but minimum tumour
dose less than 1200 r . . . . . 0/3 0/4
(None (None
survived survived
3 months) 3 months)
(e) Male patients with extra-thoracic spread and/or
metastases in ribs at first X-ray treatment . 2/9 0/7
(None
survived
more than
4 months)
Pooled Groups (a), (b), (c), (d) and (e) * * 13/26 4/30
(f) Male patients treated surgically at some stage 1/2 2/3
(g) Male patients with diagnosis not verified or not
bronchial carcinoma or adenoma . . . 2/10 318
(h) Female patients, all groups except bronchial
adenoma . . . . . . . 1/5 1/4
(i) Bronchial adenoma (both male) . . . 0/2 0
(j) No X-ray therapy; compound only . . 0/1 0
For the unselected male patients with reasonably certain diagnosis in the pooled Groups (a), (b),
(c), (d) and (e), the difference between the proportion surviving 8 months or more from the first
X-ray treatment in the two series is statistically significant; x[]2 = 8-867, so that P = 0-003.
The proportions surviving 12 months or more from the first symptom in the series X + I-VS and
X +I-MS are respectively 16/25t and 10/31; XC2 = 4-403, so that P = 0-037, which may be
regarded as significant.
t The case marked * above is transferred to the series X + I-MS.J. S. MITCHELL
(b) cases with positive histology on biopsy specimens of supraclavicular
nodes, cutaneous or other metastases but in which there was no bron-
choscopy or the bronchoscopic appearances were not definite; this
sub-group consists of 8 control cases and 8 treated cases ;
(c) one case (treated) with typical bronchoscopic appearances together
with metastases in the skin, confirmed histologically.
These additional 15 control and 18 treated cases are usually more advanced
and are in general less comparable than the " histologically verified " cases but
must be considered with them to give a complete picture. Of the combined
series of " confirmed cases," there are in all 34 in the control group, which was
treated by X-ray therapy only, and 47 in the treated group, which received X-ray
therapy together with the compound. As anticipated the results oftreatment of
the " confirmed cases " are poorer than those ofthe "histologically verified " cases.
Other groups ofcases which cannot be included in the main part ofthis investi-
gation may be summarised as follows:
(i) Cases with typical radiological appearances together with metastases at
some stage but not verified histologically and in which there was no bronchoscopy
or the bronchoscopic appearances were not definite. In these cases the diagnosis
can only be regarded as probable. In the control group, there are 12 cases; the
meantimeofsurvival is 8-50 months from the first symptomand 3-67monthsfrom
the first X-ray treatment. In the treated group, there are 13 cases; the mean
times ofsurvival are 12-15 months from the first symptom and 6*31 months from
the first X-ray treatment.
(ii) Cases rejected as unsuitable for palliative X-ray therapy. During the
control period, there were 18 ofthese cases, ofwhich 10 were histologically verified
and during the period corresponding to the treated group, there were 7 cases of
which only one was verified histologically.
The enumeration of rejected cases is unsatisfactory because of selection by
the physicians referring these advanced cases.
Hence the total number of cases with a reasonably certain or probable diag-
nosis ofinoperable carcinoma ofthe bronchus is 131. The control group is drawn
from a total of 64 cases, and the treated group from a total of 67 cases.
Histology.
Of the 19 verified control cases, there are 11 cases of stratified carcinoma, of
which 7 are squamous and 4 non-squamous, 3 cases of adenocarcinoma, 4 of an-
a plastic carcinoma and one unclassified. Of the 7 cases of squamous carcinoma,
two showed keratinisation.
Of the 29 verified treated cases, there are 17 cases of stratified carcinoma, of
which 10 are squamous and 7 non-squamous, 3 cases of adenocarcinoma, 8 of
anaplastic carcinoma and one an unusual poorly differentiated lesion.
Of the 10 cases of squamous carcinoma three cases show definite keratinisa-
tion; in two further cases there is a suggestion ofkeratinisation. It is interesting
to note that all these cases responded well to treatment.
RESULTS.
The control group was treated by X-ray therapy only, from 1943 to May,
1947. The treated group was treated by X-ray therapy combined with tetra-
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sodium 2-methyl-I: 4-naphthohydroquinone diphosphate (Compound I, Synkavit)
administered by intravenous and/or intramuscular injection from May, 1947 to
December, 1949 inclusive.
Cases verified histologically.
Cases were verified histologically mainly by bronchial biopsy and/or post-
mortem examination.
Control group: X-ray therapy only.
19 cases: mean survival 3*89 months from the first X-ray treatment and 11.00
months from the first symptom.
Only 1 case, who survived 15 months, survived more than 8 months from the
first X-ray treatment.
Three cases survived more than 15 months from the first symptom.
Treated group: X-ray therapy combined with the compound.
29 cases: mean survival 9*38 months from the first X-raytreatment and 1755
months from the first symptom.
Of these, 15 cases survived more than 18 months and 7 cases more than 15
months from the first treatment; 15 cases also survived more than 15 months
from the first symptom.
The survival time from the first X-ray treatment is significantly greater in
the treated group (mean survival 9-38 months) than in the control group (mean
survival 3589 months)-(n = 46 Student's t = 3.519, P = 0*001; using the
logarithms of the survival times, t = 4.046). Even if the cases which survived
only one month from the first X-ray treatment are excluded, to meet the criticism
of a possible difference in selection of the cases, the difference in survival after
the first treatment between the treated group (mean survival 9-68 months) and
the control group (mean survival 5-23 months) is still significant (n = 39, t
2*457, P is slightly less than 0-02). Considering the histological classification,
the only type providing adequate numbers is the stratified carcinoma. The
proportion ofcases ofstratified carcinoma is almost identical in the control (11/19)
and treated (17/29) groups. Of the cases of stratified carcinoma surviving more
than 8 months from the first X-ray treatment, there are 1 out of 11 cases ih the
control group and 11 out of 17 cases in the treated group; the survival must
be regarded as significantly greater in the treated than in the control group;
(Xc2= 6-32, P = 0'012).
It is relevant to note that the frequency distribution of survival times after
the first X-ray treatment is positively J-shaped for the control group and roughly
symmetrical, probably approximating to lognormal for the treated group. There
aresignificantly fewer short survivals in the treatedgroup than in the controlgroup,
e.g., of cases surviving 3 months or less after the first X-ray treatment, there
were 5/29 in the former and 12/19 in the latter; xC2 =8-67, P = 0-003. It
is suggested that this change in frequency distribution provides further evidence
for the reality ofthe radiosensitisation.
The survival time from the first symptom is significantly greater in the treated
group (mean survival 17-55 months) than in the control group (mean survival
11.00 months)-(n = 46, t = 2-624, P = 0.012). There is no significant differ-
ence between the time interval from the first symptom to the first treatment in
the control group (mean interval 7*11 months) and in the treated group (mean
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interval 8 17 months). It is to be noted that the treated group includes one case,
who had a history of45 months' duration before treatmnent and survived 3 months
from the first X-ray treatment.
Within the treated group, 20 cases were treated by X-ray therapy combined
with the compound administered by intravenous injection or by both intramus-
cular and intravenous injection. In this treated sub-group of 20 cases, the mean
survival time is 11-05 months and is significantly greater than the mean survival
time of3-89 months in the controlgroup of 19 cases (n - 37, t = 4-345, P <0-001).
There is suggestive evidence that X-ray therapy combined with intravenous
compound is associated with longer survival after the first X-ray treatment (18
cases, mean survival 11'17 months) than is X-ray therapy combined with intra-
muscular compound (11 cases, mean survival 6*45 months)-(n = 27, t = 2 106,
P = 0-04).
All confirmed cases.
Control group: X-ray therapy only.
34 cases: mean survival 3-82 months from the first X-ray treatment and 10-00
months from the first symptom.
Only 2 cases, which survived 12 and 15 months respectively, survived more
than 8 months from the first X-ray treatment and 4 cases survived more than
15 months from the first symptom.
Treated group: X-ray therapy combined with the compound.
47 cases: mean survival 8-72 months from the first X-ray treatment and 15-45
months from the first symptom.
Of these, 18 cases survived more than 8 months and 8 cases more than 15
months from the first X-ray treatment; 16 cases survived more than 15 months
from the first symptom.
The survival time from the first X-ray treatment is significantly greater in
the treated group (mean survival 8-73 months) than in the control group (mean
survival 3*82 months) - (n = 79, t = 3-630, P < 0-001; using the logarithms
of the survival times, t = 3-967).
The survival time from the first symptom is also to be regarded as significantly
greater in the treated group (mean survival 15-45 months) than in the control
group (mean survival 10.00 months)-(n = 79, t = 2*678, P < 0.01).
It is interesting to consider the proportion of cases surviving more than 15
months from the ilrst X-ray treatment out of the total number of cases with
reasonably certain or probable diagnosis and including those cases rejected as
unsuitable for X-ray therapy during the periods of observation. In these total
groups, there are 64 control cases (including 8 rejected) of whom none survived
more than 15 months from the first X-raytreatment and 67 treated cases (including
7 rejected) of whom 9 survived more than 15 months. This difference between
the control and treated cases is significant (X,2 = 7-25, P = 0008 and excluding
the cases rejected, X_2 = 5*73, P = 0.017).
In the group of confirmed cases, 6 control cases and 6 treated cases received
radical X-ray therapy. For these control cases, the mean survival time is 14-5
months from the first symptom and 6-3 months from the first X-ray treatment.
For the treated cases the mean survival time is greater than 22-5 months from the
first symptom and greater than 13*2 months from the first treatment. However,
322ASSESSMENT OF SYNKAVIT AS A RADIOSENSlTISER
the number of these cases is too small for the observed difference to be taken as
a real one with any certainty. It is interesting to note that the mean survival
from the first symptom in Fulton's (1949) series of 190 cases treated by radical
X-ray therapy was 14 7 months; the closeness of the aggreement is fortuitous.
This preliminary trial suggests that in the treatment of inoperable carcinoma
of the bronchus the ancillary use of Compound I produces a small but useful
increase in the length of survival. This finding is in accordance with the clinical
impressions and the small improvement in length of survival appears to be
associated with useful life.
However, this study is not entirely satisfactory in that the control group
treated by X-ray therapy only and the treated group which received X-ray therapy
combined with the compound, were treated consecutively and not within the
same period of time.
Design ofa Clinical Therapeutic Trial of a Radiosensitiser.
The design of a clinical trial to evaluate any proposed method of treatment
of cancer appears to be one of the most important problems in medicine at the
present time. The basic principles involved are well understood as a result of
the classical statistical studies ofFisher (1925, 1935) on the design ofexperiments,
and on the work of Hill (1952) on the design of clinical trials. In general, in con-
sidering therapeutic trials in the cancer field, the design must be capable ofgiving
a completely convincing statistically significant quantitative result as efficiently
as possible with a minimum number ofpatients and must be acceptable and above
reproach from the moral and ethical points of view. The most important single
feature of the design is random allocation ofthe patients to two or more alterna-
tive forms of treatment the value of which is being compared. For assessment
of the result of treatment, it is necessary to select relevant criteria capable of
objective measurement such as the survival time suitably specified. At the same
time, it is absolutely essential to provide for each individual patient treatment
which is the best possible according to present knowledge. Accordingly, it may
be, and probably often will be, necessary to plan to depart from what may be
termed the theoretically ideal form of experiment with deliberate sacrifice of
some information.
In the present example ofthe attempted evaluation oftetra-sodium 2-methyl-
1: 4-naphthohydroquinone diphosphate (Compound I, Synkavit) as a radio-
sensitiser in the radio therapy of inoperable carcinoma of the bronchus, cases
were allocated at random to one of two alternative forms of treatment, X-ray
therapy combined with Compound I administered by intravenous injection (X +
I-VS) and X-ray therapy combined with Compound I administered by intra-
musculrzr injection (X + I-MS). The latter is regarded as the control group.
The preliminary clinical studies and animal experiments suggested that the results
of X-ray therapy combined with intramuscular compound (X + I-MS) were
slightly better than those of X-ray therapy only, and that with comparable doses
of compound it was likely that X + I-VS would produce better results than
X + I-MS. The use of X + I-MS as the control group instead of, e.g., X-ray
therapy combined with distilled water, almost certainly scarifices a small amount
of information but was regarded as essential in order to give to each individual
patient the best available proven form of treatment. This type of design of a
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clinicaltherapeutic trial must bejustified aposteriori. It is necessary to -examine
the possibleimportance ofall the various factors which may be relevant including
age, sex, extent of the disease at treatment, histology and/or cytology, the mini-
mum tumour dose and overall time of radiotherapy, the total dose and overall
time of administration of the compound and in particular the certainty of the
diagnosis. Tests of heterogeneity must be made. It does not seem possible to
estimate in advance the number of patients required. This will depend on the
differences observed between the groups and subgroups. The results are likely
to be of sufficient importance to necessitate the use of stringent criteria
ofsignificance.
The randomisation was made on the basis of a provisional diagnosis ofinoper-
able carcinoma of the bronchus, made when the patient was first examined by the
staff of the Department. Some of the cases were referred with histological evi-
dence from bronchialbiopsy. In other cases, there had been no previous investi-
gation and the provisional diagnosis was based on clinical evidence only.
All cases were investigated critically, as necessary, and every effort was made
to obtain histological and/or cytological verification of the diagnosis. Almost
all the sections have been reviewed by Dr. A. M. Barrett, of the Department
of Pathology of the University of Cambridge. The samples of sputum have
been examinedmainly by Dr. J. HDean. I amindebted to Dr. D. B. Cruickshank,
of the Sims Woodhead Memorial Laboratory, Papworth, for most of the reports
on specimens of bronchial aspirate. Particular attention has been paid to the
establishment of the diagnosis of carcinoma of the bronchus and the identifi-
cation and exclusion of cases of bronchial adenoma and related tumours of low
grade malignancy apparently arising in bronchialglands. Thehistological classi-
fication of carcinoma of the bronchus is that employed by Dr. A. M. Barrett
and may be summarised as follows:
(1) Stratified carcinoma, either squamous or non-squamous, the degree of
keratinisation or differentiation being noted, (2) adenocarcinoma, (3) anaplastic
carcinoma, including " oat-celled " carcinoma, and (4) others, including " alveo-
lar " cell carcinoma and carcinoma not classifiable. The histological classification
of carcinoma of the bronchus is often difficult because of the existence of inter-
mediate types and is somewhat arbitrary in some cases.
On the clinical side, a careful and full medical examination is made, including
usually indirect laryngoscopy. It has been considered important to determine
the extent ofspread ofthe disease with special reference to the early detection of
metastases in bones. The occasional cases originally considered inoperable and
in which it has been found possible subsequently to carry out some type ofsurgery
have been considered separately in the assessment of the results. The fate of
every case included in the trial must be explicitly stated.
To obtain randomisation, the serial number of the patient in the special regi-
ster of cases ofinoperable carcinoma ofthe bronchus was taken and the correspon-
ding number read off in a table of random numbers; Table xxxiii (vi) in Fisher
and Yates (1948, p. 109) was used. For random numbers ending with an even
number or zero, the patient was allocated to receive X-ray therapy combined
with the compound administered by intravenous injection (X + I-VS); for
odd randomnumbers, thepatient was allocated toreceiveX-raytherapy combined
with intramuscular compound (X + I-MS). If there are medical contraindica-
tions to intravenous administration ofthe compoundincluding cerebral metastases
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and threatened laryngeal obstruction, where the possible risk of increased oedema
might dangerous, severe myocardial degeneration and impossible veins, and randoin corresponds to +I-VS,
the compound is given by intra-
injection, the case is still classified as I-VS,
with suitable
Similarly may occasionally be desirable to administer the compound by intravenous injection to an individual patient in the group + I-MS. This
type procedure
avoids bias in that leads to underestimation of the difference between the two groups. any case is retreated,
the compound is administered
by the route previously used.
For the purpose
of trial, the upper level of dosage of the compound admini- stered by intramuscular injection is kept at mg. daily,
while for intravenous
administration dose is increased to as high a level as is tolerated. For both
I-M I-V, dosage is started with mg.
and increased daily in steps of
mg. any undesirable reaction such as excessive coughing, nausea, faintness or discomfort or pain the chest is observed after intravenous injection, the dose
is reduced which there is no such reaction and then cautiously increa- sedagain on the following days, sometimes by steps of mg. For most patients, for intravenous injections the best maximum daily dose appears to be 100 mg.;
many
will
mg. and a few will tolerate mg.
is often necesssary
at the higher dosage levels to reduce the daily dose after a time.
With regard
to timing,
in the series of cases the injections have been given as
closely possible minutes before starting the individual X-ray treatment.
many
was only possible to start the injections on the day of the first
X-ray treatment, whenever practicable,
thei njections have been commenced
3-5 days before starting the X-ray therapy in order to reach the higher dosage
levels. general, injections are continued daily without interruption during
X-ray therapy and are stopped with the last X-ray treatment.
The compound is never administered orally in this trial.
In this trial, every endeavour has been made to employ the normal methods
X-ray therapy
to avoid any modification of the techniques as a result of
compound. The X-ray therapy has been of conventional type using
kVp X-radiation of H.V.L. 1-5 mm. copper,
with radiographic
checking thoracic field positions in most cases.
In a large proportion of
only palliative X-ray therapy was considered justifiable; the commonest
technique two fields, anterior and posterior thoracic, usually 15
cm.. 12-5
cm. diameter, with central minimum tumour dose 1500-2000 r given
overall time days. Radical X-ray therapy has been limited
usually patients good general condition with a lesion considered to be local-
though inoperable. For radical X-ray therapy,
and also for palliative X-ray
therapy cases, a four-field or six-field technique with beam direction
used; size varied between S
x cm.
and X cm.
but
was 15 X cm. The treatment
has been regarded as radical
when minimum tumour dose is r or greater in overall time days
noted that for most of the cases with overall time about
days,
treatment was of "
spaced " type, with
consecutive daily treat-
ments, days interval, then consecutive daily treatments,
days interval
finally treatments. treatment with M.T.D.
r in O.T.
days
has been classed as palliative and M.T.D.
r in O.T.
days as radical.
With regard
to general medical treatment, pyridoxine has not been used for
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radiation sickness, and the nitrogen mustards have not been used for attempted
palliation of symptoms.
RESULTS TO DATE.
The results of this clinical trial as assessed on 31 May, 1953, are summarised
in Table II. This deals with cases No. 1-91 inclusive in which the first X-ray
treatment was given between 1 April, 1951 and 31 December, 1952. Some cases
are still surviving so that additional evidence concerning the diagnosis may be
forthcoming in a few of these and the estimates of survival time are necessarily
incomplete. It is reasonably certain that any such new evidence will increase
the differences observed between the two series.
The total numbers of cases are 46 in the X + I-VS series, ofwhich one recei-
ved compound only with no X-ray therapy and 45 in the X + I-MS series.
The fate ofevery case is accounted for in the Groups (a) to (j) of Table II. The
small groups of male patients treated surgically at some stage (f) and female
patients (h) are too heterogeneous and too small to be of value in investigation.
Accurate diagnosis is of extreme importance in any studies of the treatment of
carcinoma of the bronchus and appears to present greater difficulties than are
commonly appreciated. The interpretation of bronchial biopsies is often diffi-
cult and review of the sections has led to rejection of the diagnosis of bronchial
carcinoma in three cases (No. 45, 63, 68). Positive histology on metastases in
supraclavicular nodes, skin or bone is not necessarily evidence that the primary
tumour is in a bronchus. Stringent criteria have been used in the cytological
evaluation of malignant cells in sputum and bronchial aspirate. It is interesting
that in Group (g) in which the diagnosis of bronchial carcinoma was unverified
or probably incorrect, the results included some which at first consideration
appeared to be among the most satisfactory.
The evidence to date presented in Table II shows that both for the selected
treatable male patients with less advanced inoperable carcinoma of the bronchus
in Groups (a), (b) and (c), and for all the male patients, not treated surgically
and withreasonably certain diagnosis in the Groups (a), (b), (c), (d) and (e), a sub-
stantiallylarger proportion survive 8 months or more from the first X-ray treat-
ment when this is combined with intravenous Compound I than when combined
with intramuscular compound. The proportions are 11/14 for X + IV-S as
compared with 4/19 for X + I-MS for pooled Groups (a), (b) and (c), and 13/26
for X + I-VS as compared with 4/30 for X + I-MS for the pooled Groups
(a) to (e). Survival statistics are as yet incomplete but in the pooled Groups
(a), (b) and (c)-with transfer of the case marked * to the X + I-MS series
-the estimated survival time from the first X-ray treatment is significantly
larger in the X + I-VS series (mean survival 10-8 months) than in the X +
I-MS series (mean survival 5*9 months)-(n = 31, t = 2-701, so that P = 0-011).
As the number of cases increases, the significance of the various differences
between the two series increases.
Survival from the first symptom is a less sensitive and less objective test.
In some of the groups, the differences between the times of survival from the
first symptom in the two series are suggestive but not really convincing. For
the pooled Groups (a), (b), (c), (d) and (e), if the case marked * is transferred to
the series X + I-MS, the proportions surviving 12 months or more from the
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first recorded symptom in the series X + I-VS and X + I-MS are respectively
16/25 and 10/31; with Yates's correction for continuity X02 = 4-403 so that
P = 0 037; thus the difference between these two groups can be regarded as
significant.
It is necessary to consider the composition of the various groups in the two
series in Table I. Histological classification is possible for all cases in Groups
(a) and (b). There were no cases of adenocarcinoma. In the X + I-VS series,
therewere 9 cases ofstratified carcinoma-7 squamousincluding onemixedform-
and 7/9 including one anaplastic carcinoma survived 8 months or more from
the first X-ray treatment. In the X + I-MS series, there were 14 cases of
stratified carcinoma ofwhich 11 were squamous and of which only 4, 3 squamous
and one non-squamous, survived 8 months or more from the first X-ray treatment.
The difference in survival in these small groups in the two series is suggestive.
The methods of X-ray therapy and administration of the compound are
not significantly different in the two series and fortunately such differences as
are found might be considered as tending in all instances to reduce the observed
differences in survival between the two series. Considering the Groups (a), (b)
and (c), for the 14 patients in the X + I-VS series, only one received radical
treatment, and this case survived 8 months. The mean M.T.D. was 1,806 r
delivered in mean O.T. 11 4 days; and the mean amount of compound used was
757 mg. administered in mean O.T. 12*4 days; for the 19 patients in the X +
I-MS series, 4 received radical treatment and survived respectively 4, 6, 7 and
6 months, the mean M.T.D. was 2,065 r delivered in mean O.T. 18&5 days and the
mean amount of compound used was 950 mg. administered in mean O.T. 20 days.
The age at treatment in the X + I-VS series had a mean of 581 years with
extremes of 44 and 72 years, and in the X + I-MS series, a mean of 52-8 years
with extremes of 40 and 68 years.
None of these differences between the two series is statistically significant.
For 31 degrees of freedom, for the differences for mean M.T.D., t = 0-924 and
P = 0-36; for mean overall time of X-ray therapy t = 1*486, and P = 0-15, for
mean amount of Compound t = 101 and P = 0-32; for mean overall time of
administration of Compound t 1- 602 and P = 0 11; and for mean age at the
first treatment t = 1621 and P 0- 11.
Accordingly, it would appear to be justifiable to conclude that the results
obtained so far in this clinical trial indicate that intravenous administration of
Compound I (Synkavit) has a small but useful effect as a clinical radiosensitiser
in the radiotherapy of inoperable cases of carcinoma of the bronchus. However,
further evidence is desirable.
SUMMARY.
An attempt has been made to assess the clinical value of tetra-sodium 2-
methyl-I: 4-naphthohydroquinone diphosphate (Synkavit) as a radiosensitiser
in the radiotherapy of malignant tumours.
A preliminary general survey of the use of the compound in the treatment of
patients with various types of malignant tumour other than carcinoma of the
bronchus with follow-up for at least three and a half years is summarised. The
results suggest that the proportion of cases showing unexpectedly good clinical
response is greater with radiotherapy combined with the compound administered
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by intravenous injection than with radiotherapy combined with the compound
administered by intramuscular injection.
Preliminary clinicalstudies oftheinfluenceofthe ancillaryuse ofthe compound
on the survival times of inoperable cases of carcinoma of the bronchus treated
by X-ray therapy are discussed in some detail and the end results summarised.
The design of a clinical therapeutic trial of a radiosensitiser is discussed, with
special reference to the evaluation of tetra-sodium 2-methyl-I: 4-naphthohydro-
quinone diphosphate M a radiosensitiser in the radiotherapy of inoperable cases
of carcinoma of the bronchus. The results of this clinical trial are summarised
to date.
It is concluded that intravenous administration of this compound (Synkavit)
has a small but useful effect as a clinical radiosensitiser.
In this work I have been helped by many colleagues at Addenbrooke's Hos-
pital. In particular I wish to thank Dr. A. M. Barrett and Dr. WV. Paton Philip,
and Miss E. J. Porter, Sister-in-Charge of the Radiotherapeutic Centre and
her staff.
I wish to thank Dr. F. Wrigley and Dr. A. L. Morrison, of Roche Products
Limited, Wewyn Garden City, for supplies of Synkavit.
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